Search Results for: wake forest stem cell bladder atala

Newswise CHICAGO (June 10, 2022): Anthony Atala, MD, FACS, Winston-Salem, North Carolina, will be presented with the 2022 Jacobson Innovation Award of the American College of Surgeons (ACS) at a dinner held in his honor this evening in Chicago. He is currently the George Link, Jr. Professor and Director of the Wake Forest Institute for Regenerative Medicine (WFIRM) and the W. H. Boyce Professor and Chair of Urology at the Wake Forest University School of Medicine.

The international surgical award from the ACS honors living surgeons who are innovators of a new development or technique in any field of surgery. It is made possible through a gift from Julius H. Jacobson II, MD, FACS, and his wife Joan. Dr. Jacobson is a general vascular surgeon known for his pioneering work in the development of microsurgery.

Dr. Atala is a pediatric urologist, researcher, professor, and mentor who is renowned for developing foundational principles for regenerative medicine research, which holds great promise for people who require tissue substitution and reconstruction. Dr. Atala and his team successfully implanted the worlds first laboratory grown bladder in 1999.

Dr. Atalas remarkable work has expanded, and today, WFIRM is a leader in translating scientific discovery into regenerative medicine clinical therapies. He currently leads an interdisciplinary team of more than 450 researchers and physicians. Beyond many other world firsts, WFIRM has also developed 15 clinically used technology-based applications, including muscle, urethra, cartilage, reproductive tissues, and skin. Currently, the Institute is working on more than 40 tissues and organs.

Through Dr. Atala's vision, ingenuity, and leadership, the WFIRM team has developed specialized 3-D printers to engineer tissues. This work is accomplished by using cells to create various tissues and organs, including miniature organs called organoids to create body-on-a-chip systems. Dr. Atala and his team also discovered a stem cell population derived from both the amniotic fluid and the placenta, which are currently being used for clinically relevant research applications.

Dr. Atala's theory is that every cell within the human body should be capable of regeneration. What reproduces naturally inside the body should also have the same capabilities of reproduction outside of the body. According to Dr. Atala, the key benefit to the approach of cell and tissue regeneration is that a patient will not reject their own cells or tissue, which is always a concern related to traditional organ match transplantation.

Honors and awards Dr. Atalas innovative work has been recognized as one of Time magazine's Top 10 Medical Breakthroughs in 2007, Smithsonian's 2010 Top Science Story of the Year, and U.S. News & World Report's honor as one of 14 top Pioneers of Medical Progress in the 21st Century. He has been named by Scientific American as one of the world's most influential people in biotechnology, by Life Sciences Intellectual Property Review as one of 50 Key Influencers in the Life Sciences Intellectual Property arena, and by Nature Biotechnology as one of the top 10 Translational Researchers in the World.

Dr. Atala was elected to the Institute of Medicine of the National Academies of Sciences (now the National Academy of Medicine) in 2011 and inducted into the American Institute for Medical and Biological Engineering. In 2014, he was inducted into the National Academy of Inventors as a Charter Fellow and has been a strong and thoughtful contributor to the ACS Surgical Forum and Surgical Research Committee. He presented the prestigious Martin Memorial Named Lecture during the ACS Clinical Congress in 2010 entitled, Regenerative Medicine: New Approaches to Health Care.

Other honors include being the recipient of the U.S. Congress-funded Christopher Columbus Foundation Award, which is bestowed on a living American that currently is working on a discovery that will significantly affect society; the World Technology Award in Health and Medicine for achieving significant and lasting progress; the Edison Science/Medical Award; and the Smithsonian Ingenuity Award.

A national leader in regenerative medicine Throughout his distinguished career, Dr. Atala has led or served on several national professional and government committees, including the National Institutes of Health Working Group on Cells and Developmental Biology, the National Institutes of Health Bioengineering Consortium, and the National Cancer Institute's Advisory Board. He is a founder of the Tissue Engineering Society, the Regenerative Medicine Society, the Regenerative Medicine Foundation, the Alliance for Regenerative Medicine, the Regenerative Medicine Development Organization, the Regenerative Medicine Manufacturing Society, and the Regenerative Medicine Manufacturing Consortium.

A prolific author and inventorDr. Atala is the editor in chief of Stem Cells-Translational Medicine and BioPrinting. He is an author or coauthor of more than 800 journal articles and has applied for or received over 250 national and international patents.

# # #

About Anthony Atala, MD, FACS

Dr. Atala was born in Lima, Peru, and moved to the United States with his family when he was a young boy. He earned a Bachelor of Arts degree from the University of Miami before attending medical school at the University of Louisville, where he also completed his surgical residency training. Near the end of his residency, he applied for a pediatric urology fellowship at Boston Children's Hospital, which was transitioning from a one-year to a two-year program to include a year of research prior to the clinical year. He embarked on a fellowship there in its new form with encouragement from Alan B. Retik, MD, FACS, founder of Boston Childrens first department of urology. Dr. Atala arrived in Boston and began attending seminars, which led him to explore whether uroepithelial cells could be grown and expanded ex vivo, comparable to skin. This additional year of research sparked what has become his career of transformational research, discovery, and innovation with his work focused on growing human cells, tissues, and organs.

Dr. Atala spent the first portion of his academic career at Harvard Medical School before being recruited in 2004 as professor and chair of the department of urology at Wake Forest School of Medicine. After moving his laboratory from Boston, he became the founding Director of the Wake Forest Institute for Regenerative Medicine, where his research and work has produced extraordinary results for nearly two decades.

About the American College of Surgeons The American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for all surgical patients. The College is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The College has more than 84,000 members and is the largest organization of surgeons in the world. "FACS" designates that a surgeon is a Fellow of the American College of Surgeons.

View original post here:
Pediatric Urologist Dr. Anthony Atala to Receive 2022 Jacobson Innovation Award of the American College of Surgeons for Pioneering Work in...

WINSTON-SALEM Human organ transplants became possible in 1954 when a kidney became the first organ to be transplanted successfully, eventually earning Boston physician Joseph Murray the Nobel Prize.

Today, its also possible to receive a transplanted heart, lungs, liver, pancreas or intestines, as well as tissues including skin, bone, corneas, tendons, ligaments and blood vessels.

A record-high number of organ transplants 41,354 were performed in the United States in 2021, according to the United Network for Organ Sharing, a nonprofit organization that supports the nations transplant system. It was the first year that organ transplants exceeded 40,000.

Despite the progress made in organ transplantation over the last seven decades, the demand for organs still greatly out-strips the supply, a trend unlikely to reverse.

Even though organ transplants are out there, the challenge is that more patients are dying every day from organ failure, and the numbers are fairly shocking actually, saidAnthony Atala, M.D., an internationally acclaimed urologist, researcher and professor at the Wake Forest University School of Medicine. So thats where regenerative medicine comes in.

Atala is director of theWake Forest Institute for Regenerative Medicine(WFIRM), a translational research organization devoted to bringing new treatments and cures to patients with diseased or damaged organs or tissues. He highlighted WFIRMs activities and impact as the keynote speaker at Triad BioNight, a dinner and awards event held June 23 at High Point University and sponsored by the North Carolina Biotechnology Center.

Piedmont Triad bioscience leaders honored with awards at Triad BioNight

Atalas appearance at the event reinforced the mutual admiration between him and NCBiotech that dates back to his arrival at the Triad university in 2004. The Biotech Center has awarded numerous grants to various members of his lab over the years, and Atala has also served on the NCBiotech board of directors.

NCBiotech has provided $352,476.32 in grants to Wake Forest University for regenerative medicine-associated research during Atalas 18 years at the university. The Center has awarded an additional $75,883.62 in meeting, event, and educational grants for regenerative medicine-related programming during the same time, including an active $10,000 award for an upcoming meeting.

It is clear to see how over time, this regional effort has global impact, said Nancy Johnston, executive director of NCBiotechs Piedmont Triad Office. New initiatives underway indicate there is power in partnerships and place; value in investing in innovation; and the top talent it takes in this emerging field of regenerative medicine.

Regenerative Medicine The Driving Force for Dr. Anthony Atala

Atala told the crowd of nearly 400 attendees that WFIRMs scientists, technicians and physicians are working on regenerative medicine therapies for about 40 different organs and tissues, building on 15 applications that have been used in patients to date.

We have an amazing team over 450 people all working together to bring these technologies from the bench to the bedside, Atala said.

WFIRM is based in a five-story building spanning about 200,000 square feet in Winston-SalemsInnovation Quarter, a downtown district devoted to research and technology enterprises.

We do everything here, from the idea, to the concepts, to the proof of principle at the benchtop, to the preclinical work, all the way to the manufacturing of the product in an FDA-compliant facility right in this building, Atala said.

WFIRM scientists and physicians made history in 1999 when they were the first in the world to implant laboratory-grown organs into humans.Seven children with spina bifida and severely malfunctioning bladders received grafts of rudimentary bladders engineered in Winston-Salem.

Today WFIRMs multidisciplinary work uses cells, bioreactors, tissue engineering, biomaterials, 3D bioprinting, small molecules, gene editing, body-on-a-chip technologies and personalized medicine approaches to innovate new therapies and diagnostics.

NC bio startup raises $15.5M to advance 4D printing of human organs

Cell therapy the use of harvested and cultured cells to restore tissues and organs is a major thrust of WFIRMs work. The technology offers a great advantage over donated organs and tissues because it typically uses a patients own cells, thereby avoiding rejection by the bodys immune system.

Working with cell media in the Atala lab.

Work is under way at WFIRM to use skeletal muscle cells to restore lost muscle function in patients with urinary incontinence and in patients undergoing rotator cuff repair surgery.

In both cases, skeletal muscle cells are collected from a tissue sample smaller than a postage stamp, are multiplied in the lab, and are then injected into the body to build muscle.

Researchers are also working with a type of stem cell taken from the amniotic fluid or placenta after a woman gives birth. WFIRM scientists were the first in the world to identify and characterize stem cells derived from amniotic fluid in 2007 and since then have developed techniques for isolating and expanding the cells.

These cells are very powerful, Atala said. They can grow into all three different major categories of cells that lead to every cell in your body.

WFIRM is investigating the use of these cells as potential therapies for patients with chronic kidney disease.

W-S biotech firm Plakous Therapeutics wins NC BIONEER Venture Challenge

Cell therapy often involves the use of biomaterials that can be shaped into scaffolds that mimic the shape of a tissue or organ. Different materials can be mixed and matched for various tissue reconstruction.

One application is for helping patients with a damaged urethra, the duct that drains urine from the bladder. A tubular-shaped scaffold is coated inside and outside with muscle cells that are taken from the patient and multiplied, then the scaffold is placed in an oven-like device to encourage cell growth.

Its very much like baking a layer cake, Atala said, eliciting chuckles from the audience. Once its completed you actually put it back into the patient.

The implanted scaffold biodegrades in the body after six months, but the cells remain viable indefinitely.You end up with your very own cells, your very own bridge and your very own organ, Atala said.

WFIRM researchers have successfully engineered replacement tissues and organs of all four shapes found in the body flat structures, tubular tissues, hollow organs and solid organs.

Federal grant will boost training opportunities for students in regenerative medicine

WFIRM is also a pioneer in 3D bioprinting, the use of printer-like devices to deposit layers of living cells in three-dimensional patterns. The invention, inspired by desktop ink jet printers, brings precision and automation to the construction of tissues and organs.

Last year two teams of scientists from WFIRM used 3D bioprinting to win first and second place in NASAsVascular Tissue Challenge, a national competition to accelerate tissue engineering innovations that might benefit people on Earth today and space explorers in the future.

The WFIRM teams created lab-grown human liver tissues that were strong enough to survive and function in ways similar to those inside the body. They each used a varied 3D printing technique to construct a cube-shaped tissue about one centimeter thick and capable of functioning for 30 days in the lab.

That was a major challenge, Atala said, because anything over the size of a pinhead will not get nutrition.

Tissues in the body rely on blood vessels to supply cells with nutrients and oxygen and remove metabolic waste. Recreating this process in engineered tissue is difficult, so NASA asked teams to develop and test strategies for making tissues with functional artificial blood vessels.

Wake Forest researchers win NASA challenge to develop lab-grown human vascular tissue

The winning teams used 3D printing to create gel-like molds with a network of channels designed to maintain sufficient oxygen and nutrient levels to keep the constructed tissues alive.

The two teams collectively won $400,000 while no other team in the national competition qualified for third place.

Another WFIRM application of 3D bioprinting is body-on-a-chip technology, which applies cells onto a computer chip to mimic organs.

We can create miniature hearts, lungs, blood vessels, kidneys and brains, put them all together on a chip and actually start to screen drugs over time, Atala said.

The technology can also be used to create tumors on a chip for personalized medicine. Tumor cells harvested from tissue biopsied at the time of a patients cancer diagnosis are applied to a chip and then tested against various chemotherapy drugs so we can best predict what the best treatment is for that patient, before that patient gets the treatment, Atala said.

The cell therapy, 3D bioprinting and body-on-a-chip technologies are just a sampling of WFIRMs work, and we have a lot of things going on, Atala said.

Our mission is to bring these technologies to patients, to improve patients lives through regen med, he said. Our vision is to lead a global transformation from treatments to cures.

Wake Forest Institute for Regenerative Medicine leads new $20M effort (+ video)

Beyond its own research, WFIRM has become a major influencer and resource in regenerative medicine nationally and globally.

It has over 400 research collaborations with scientists across the United States and around the world.

Specialized containers for cell processing.

For most of these collaborations, WFIRM is the one thats providing materials, reagents, cells and know-how, trying to disseminate this information to a global scale, Atala said.

WFIRM also helps prepare the next generation of regenerative medicine scientists through education and training programs for high school students, undergraduates, graduate students and post-doctoral fellows. It also sponsors conferences and workshops, provides content and materials for museum exhibits around the world and publishes textbooks.

The institute has spurred new initiatives and entities in Winston-Salem to advance regenerative medicine nationally and globally. This ecosystem, called the Regenerative Medicine Hub, includes the nonprofit RegenMed Development Organization (ReMDO), a research partner with WFIRM that sponsors several programs to advance the field nationwide, including the Regenerative Manufacturing Innovation Consortium and the Regenerative Medicine Manufacturing Society.

Startup Spotlight: RegeneratOR Test Bed in W-S aims to boost startups focusing on regenerative medicine

Through its RegeneratOR initiative, ReMDO sponsors three programs to support startup and growth companies in regenerative medicine:

These and other resources in the Regenerative Medicine Hub have attracted about30 bioscience companiesto Winston-Salems Innovation Quarter, ranging from local start-ups to multinational corporations.

The latest company to establish a presence at ReMDOs Innovation Accelerator is Houston-basedAxiom Space, developer of the first commercial space station that will supplement and eventually replace the International Space Station.

Axiom will partner with WFIRM and ReMDO to focus on innovations in regenerative medicine manufacturing in space. Research done on the new space station, in low orbit 250 miles above Earth, will be free from the constraints of gravity, providing potential benefits.

Space station builder to lease space in Winston-Salem regenerative medicine accelerator

WFIRM and Winston-Salem have staked an early claim in a promising industry that appears destined for robust growth.

Various consultants reports predict the global market for regenerative medicine will expand at a compound annual growth rate ranging from 9 to 23% during this decade. By 2030 the market will be worth up to $150 billion, according to a report by Verified Market Research of Jersey City, N.J.

Driving that growth are an aging population battling chronic diseases, rising investments in regenerative medicine research, and advances in new technologies and therapies such as those being developed by WFIRM.

Regenerative medicine is an emerging field, Atala said. Were still trying to figure out what is the best next thing that we can do to advance these technologies.

NCBiotech Center

Link:
W-S organization working on regenerative therapies for 40 organs, tissues - WRAL TechWire